Short answer
Aldeyra Therapeutics, Inc. (ALDX) filed an 8-K current report with the SEC on June 10, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Darlene Deptula-Hicks appointed Class III director through 2029 annual meeting.
Aldeyra Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Darlene Deptula-Hicks appointed Class III director through 2029 annual meeting
- New independent Audit Committee Chair and SEC-qualified audit committee financial expert
- Initial option for 94,313 shares, vesting ratably over three years
- Annual compensation includes $40,000 director fee and $7,500 Audit Committee Chair fee
- Annual equity grants approximate $130,000 for board service and $15,000 for Audit Committee Chair service
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Todd C. Brady, M.D., Ph.D. elected Class III director through 2029; 23.0M votes for versus 1.1M withheld
- BDO USA, P.C. auditor appointment ratified for fiscal 2026; 43.7M votes for versus 321,501 against
- Executive compensation approved advisory basis; 19.5M votes for versus 4.5M against
- 44.3M shares represented, equal to 73.4% of voting shares and establishing quorum
Item 7.01 · Regulation FD Disclosure
- Board appointment of Ms. Deptula-Hicks disclosed under Regulation FD
- Leadership and governance update; investor relevance depends on her experience and committee responsibilities
- Press release furnished as Exhibit 99.1 for appointment details
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Aldeyra Therapeutics, Inc. 8-K filings
Get the next ALDX 8-K as it lands
Follow ALDX for push alerts, or ask the research agent what this filing means.